An information leaflet for patients receiving treatment by intravitreal drug injections. Recommendations of the Expert Council on retinal and optic nerve diseases of the Association of Ophthalmologists, an All-Russian public organization

Нероев, В. В.; Коротких, С. А.; Bobykin, E. V.; Зайцева, О В; Lisochkina, Alla B.; Brovkina, A F; Будзинская, М. В.; Gatsu, M.V.; Григорьева, Н. Н.; Измайлов, А. С.; Карлова, Е. В.; Ковалевская, М. А.; Nechiporenko, P. A.; Панова, И. Е.; Рябцева, А. А.; Simonova, S V; Тульцева, С. Н.; Фурсова, А. Ж.; Шадричев, Ф. Е.; Shishkin, М.М.

doi:10.21516/2072-0076-2021-14-2-supplement-7-19

Cited by 5 publications

(1 citation statement)

References 16 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Разработанный лифлет посвящен актуальной проблеме и получил высокую оценку как специалистов, так и пациентов. Экспертный совет по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации «Ассоциация врачей-офтальмологов» рекомендовал брошюру «Интравитреальные инъекции (информация для пациентов)» для использования в клинической офтальмологической практике в Российской Федерации [26]. В ноябре 2021 г., примерно через полгода после начала практического использования лифлета, нами разработана анкета и начат опрос российских врачей-офтальмологов о практических аспектах его использования.…”

Section:  результаты и обсуждениеunclassified

Информационная Поддержка Пациентов, Получающих Лечение С Применением Интравитреальных Инъекций Лекарственных Препаратов

Нероев¹,

Зайцева²,

Коротких³

et al. 2021

Офтальмология. Восточная Европа

View full text Add to dashboard Cite

Цель. Разработать и провести клиническую апробацию информационной листовки для пациентов, получающих лечение с применением интравитреальных инъекций (ИВИ). Материалы и методы. В 2020 г. экспертным советом по заболеваниям сетчатки и зрительного нерва Общероссийской общественной организации «Ассоциация врачей-офтальмологов» разработана информационная листовка «Интравитреальные инъекции (информация для пациентов)», содержащая краткие сведения о том, что представляет собой процедура, противопоказаниях, нюансах подготовки, обычных и требующих обращения за неотложной помощью симптомах течения послеоперационного периода. Исходя из принятых принципов оформления информации для пациентов, был разработан макет. Четырехстраничный лифлет (сложенный лист, отпечатанный с двух сторон) формата А4 содержит актуальные вопросы и ответы на них и выполнен в дизайне, который облегчает чтение и является «дружественным» для пожилых людей и пациентов со сниженным зрением. Для всесторонней оценки качества листовки были использованы различные подходы: определение простоты чтения текста с помощью специальных индексов, анализ качества содержания медицинской информации, а также многоцентровой опрос пациентов (n=93) с помощью оригинальной анкеты. Результаты. Анализ, проведенный с использованием онлайн-инструмента PlainRussian.ru, показал средний уровень читабельности текста лифлета. Содержание брошюры получило высокую оценку специалистов (сторонних экспертов-офтальмологов), оценивавших его с помощью инструмента The DISCERN tool. Лифлет был позитивно воспринят пациентами, принявшими участие в опросе: 91,4% дали общую оценку «отлично» или «хорошо»; 90,3% сообщили, что представленная информация полностью или по большей части соответствует их опыту лечения с применением ИВИ; 88,2% не испытали сложностей с прочтением листовки. При этом была установлена недостаточная осведомленность пациентов по вопросам, связанным с получаемым лечением, а также выявлены сложности с восприятием информации о здоровье. Этот факт подчеркивает важность информационной поддержки пациентов. Заключение. На основании результатов всесторонней оценки лифлет «Интравитреальные инъекции (информация для пациентов)» был рекомендован для применения в клинической практике здравоохранения. Purpose. To develop and clinically assess an information leaflet for patients receiving treatment with intravitreal injections (IVI). Methods. In 2020, the Expert Council on Retinal and Optic Nerve Diseases of the All-Russian Public Organization "Association of Ophthalmologists" developed an information leaflet "Intravitreal injections (information for patients)", containing brief information on what the procedure is, contraindications, preparation nuances, symptoms of the postoperative period - common and requiring emergency care. In accordance with providing an information for patients principles, a layout was developed. The A4 4-page leaflet (folded sheet, printed on both sides) contains current questions and answers in order that makes it easier to read and is "friendly" for the elderly and visually impaired patients. For a comprehensive assessment of the quality of the leaflet, various approaches were used: determining the ease of reading the text using special indices, analyzing the quality of the content of medical information, as well as a multicenter survey of patients (n=93) using the original questionnaire. Results. The analysis carried out using the online tool "PlainRussian.ru" showed an average level of readability of the leaflet text. The content of the brochure was highly valued by experts (external experts-ophthalmologists) who evaluated it using The DISCERN tool. Leaflet was positively marked by the patients who took part in the survey: 91.4% gave an overall rating of "excellent" or "good"; 90.3% reported that the information provided fully or largely corresponds to their experience with IVI treatment; 88.2% did not experience any difficulties with reading the leaflet. At the same time, a lack of awareness of patients on issues related to the treatment received was established, and difficulties with the perception of information about health were identified. This fact underlines the importance of patient information support. Conclusion. Based on the results of a comprehensive evaluation, the leaflet "Intravitreal Injections (Information for Patients)" was recommended for use in clinical healthcare practice.

show abstract

Section:  результаты и обсуждениеunclassified

Информационная Поддержка Пациентов, Получающих Лечение С Применением Интравитреальных Инъекций Лекарственных Препаратов

Нероев¹,

Зайцева²,

Коротких³

et al. 2021

Офтальмология. Восточная Европа

View full text Add to dashboard Cite

show abstract

Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration

Likhvantseva,

Gevorgyan,

Kapkova

et al. 2024

Oftalʹmologiâ

View full text Add to dashboard Cite

Purpose: to assess hypertension as a risk factor for a poor response to antiangiogenic therapy.Patients and methods. Systemic blood pressure was studied in 84 patients (92 eyes) with age-related macular degeneration who were treated with intravitreal injections of Eilea in a fixed mode.Results. It was found that significantly more often a poor response to treatment in the form of partial non-resposing or progression of the disease, despite treatment, is associated with elevated diastolic blood pressure (DBP, p = 0.01). An increase in systolic (SBP) blood pressure in patients with arterial hypertension and AMD is accompanied by an increase in eye perfusion pressure (p < 0.01), which apparently worsens the absorption of angiostatics and causes a poor response to treatment. According to the results of the study, the most favorable corridor of SBP values associated with ideal response is in the range of values of 104–140 mm Hg, and DBP is in the range of 68–80 mm Hg st., which should be taken as the recommended parameters of blood pressure in patients with nVMD receiving a course of treatment for Eylea. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to treatment with nVMD with line 1 anti-VEGF therapy drugs. Intraocular pressure (IOP) has demonstrated itself as a second modifiable independent and independent risk factor for poor response to nVMD treatment with line 1 anti-VEGF therapy drugs. The biomarker associated with the ideal response was — 12.6 mm Hg, and the corridor of recommended values — 11–21 mm Hg. An increase in ophthalmotonus with the output of personalized values beyond this corridor seems to worsen the outcome of treatment.Conclusion. The identification of modifiable risk factors is extremely important in practical ophthalmology, as it opens up the possibility of increasing the patient’s chances of a better treatment outcome. Modifiable risk factors are valuable and powerful tools that replenish our arsenal. Information about them is important not only in the treatment of AMD, but can also be the patient’s motivation for switching to a healthy lifestyle and reducing the risk of developing the disease.

show abstract

Obesity as a Risk Factor for the Ineffectiveness of Antiangiogenic Treatment of Neovascular Age-related Macular Degeneration

Likhvantseva,

Gevorgyan,

Kapkova

et al. 2024

Oftalʹmologiâ

View full text Add to dashboard Cite

Purpose: evaluation of obesity as a risk factor for poor outcome (ineffectiveness) of antiangiogenic treatment of patients with neovascular AMD.Patients and methods. Body mass index (BMI) was studied in 84 patients (92 eyes) with neovascular AMD who were treated with intravitreal injections of Eilea in a fixed mode.Results. It was found that a poor treatment outcome in the subgroup with disease progression was associated with obesity of 1–2 degrees; the average BMI in this subgroup (with a deterioration in the morphostructural parameters of the retina) significantly exceeds the indicators of ideal respondents, for comparison: 31.5 ± 0.8 versus 28.6 ± 1.1 (p = 0.04); and the incidence of obese individuals is dominant: 72 %. At the same time, a moderate inverse reliable relationship of BMI with another risk factor — systolic blood pressure (SBP) was found. In this regard, we suggested that obesity indirectly affects the outcome of treatment, since it is “tied” to systolic blood pressure (p = 0.01). An argument in favor of this assumption is a higher correlation coefficient of SAD with the outcome of treatment. The authors hypothesized that obesity contributes to the development of hypertension by increasing the risk of poor outcome of nAMD treatment. The hypothesis explained the association of obesity with the progression of morphostructural changes in the retina in the group of non-responsents with nAMD.Conclusion. Studies have demonstrated a causal relationship between obesity and the outcome of antiangiogenic treatment of patients with nAMD. The data obtained allow us to attribute OBESITY to moderate risk factors for a poor outcome of antiangiogenic treatment of patients with nAMD. Taking into account the fact that OBESITY is a modifiable factor that can be eliminated with certain efforts, opportunities are revealed to reduce the risk of an unfavorable outcome of treatment of patients with nAMD.

show abstract

An information leaflet for patients receiving treatment by intravitreal drug injections. Recommendations of the Expert Council on retinal and optic nerve diseases of the Association of Ophthalmologists, an All-Russian public organization

Cited by 5 publications

References 16 publications

Информационная Поддержка Пациентов, Получающих Лечение С Применением Интравитреальных Инъекций Лекарственных Препаратов

Информационная Поддержка Пациентов, Получающих Лечение С Применением Интравитреальных Инъекций Лекарственных Препаратов

Systemic Arterial Hypertension and Ophthalmohypertension as Independent Risk Factors for Poor Response to Antiangiogenic Therapy with Line 1 Drugs in Neovascular Age-related Macular Degeneration

Obesity as a Risk Factor for the Ineffectiveness of Antiangiogenic Treatment of Neovascular Age-related Macular Degeneration

Contact Info

Product

Resources

About